Eliezer J Barreiro

List of Publications by Year
in descending order

176 papers	8,842 citations	66343 42 h-index	48315 88 g-index
184 all docs	184 docs citations	184 times ranked	10888 citing authors

#	Article	IF	Citations
1	Comparative chemical and biological hydrolytic stability of homologous esters and isosteres. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 718-727.	5.2	6
2	Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M^{PRO}) through in silico screening supported by molecular docking and a fragment-based pharmacophore model. RSC Medicinal Chemistry, 2021, 12, 110-119.	3.9	16
3	Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514. Molecules, 2021, 26, 4828.	3.8	0
4	Effect of Sâ€“Se Bioisosteric Exchange on Affinity and Intrinsic Efficacy of Novel N-acylhydrazone Derivatives at the Adenosine A2A Receptor. Molecules, 2021, 26, 7364.	3.8	0
5	Î²-lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2020, 208, 112829.	5.5	227
6	Novel VEGFRâ€2 inhibitors with an Nâ€acylhydrazone scaffold. Archiv Der Pharmazie, 2020, 353, e2000130.	4.1	3
7	New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis . Drug Design, Development and Therapy, 2020, Volume 14, 3337-3350.	4.3	4
8	Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38Î± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7347-7354.	6.4	14
9	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. Topics in Medicinal Chemistry, 2020, , 155-201.	0.8	0
10	Novel phosphatidylinositol 4-kinases III beta (PI4KIIIÎ²) inhibitors discovered by virtual screening using free energy models. Journal of Computer-Aided Molecular Design, 2020, 34, 1091-1103.	2.9	4
11	Carbamoyl-N-aryl-imine-urea: a new framework to obtain a putative leishmanicidal drug-candidate. RSC Advances, 2020, 10, 12384-12394.	3.6	2
12	What is hidden in the biodiversity? The role of natural products and medicinal chemistry in the drug discovery process. Anais Da Academia Brasileira De Ciencias, 2019, 91, e20190306.	0.8	5
13	Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats. Pharmacological Reports, 2019, 71, 1190-1200.	3.3	5
14	LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice. European Journal of Pharmacology, 2019, 863, 172662.	3.5	7
15	Gastroprotective effects of N-acylarylhydrazone derivatives on ethanol-induced gastric lesions in mice are dependent on the NO/cGMP/KATP pathway. Biochemical Pharmacology, 2019, 169, 113629.	4.4	14
16	Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Frontiers in Pharmacology, 2019, 10, 628.	3.5	2
17	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	3.3	28
18	Chemical Intuition in Drug Design and Discovery. Current Topics in Medicinal Chemistry, 2019, 19, 1679-1693.	2.1	10

#	Article	IF	Citations
19	Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized. Toxicon, 2018, 144, 75-82.	1.6	4
20	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. Journal of Medicinal Chemistry, 2018, 61, 5805-5821.	6.4	343
21	Discovery of naphthylâ€‹Nâ€acylhydrazone p38Î± MAPK inhibitors with in vivo antiâ€inflammatory and antiâ€TNFâ€Î± activity. Chemical Biology and Drug Design, 2018, 91, 391-397.	3.2	22
22	Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization. Letters in Drug Design and Discovery, 2018, 15, 778-786.	0.7	4
23	Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative. Pharmaceuticals, 2018, 11, 119.	3.8	7
24	Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction. International Immunopharmacology, 2018, 65, 108-118.	3.8	6
25	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1073-1088.	0.8	3
26	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	2.2	140
27	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	2.5	8
28	A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug. Journal of Molecular Structure, 2017, 1146, 735-743.	3.6	3
29	The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology, 2017, 69, 1374-1380.	2.4	3
30	Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. Journal of Molecular Structure, 2017, 1147, 226-234.	3.6	10
31	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2017, 8, 858.	3.5	27
32	Adenosine A_{2A} receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Design, Development and Therapy, 2017, Volume11, 553-562.	4.3	31
33	Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents. Drug Design, Development and Therapy, 2016, Volume 10, 2869-2879.	4.3	12
34	Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 315-323.	2.5	18
35	LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349.	1.7	7
36	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. International Journal of Biological Macromolecules, 2016, 82, 663-670.	7.5	33

#	Article	IF	Citations
37	Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. PLoS ONE, 2016, 11, e0162895.	2.5	10
38	Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives. Molecules, 2015, 20, 3067-3088.	3.8	39
39	Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema. Frontiers in Physiology, 2015, 6, 267.	2.8	18
40	Structural feature evolution â€“ from fluids to the solid phase â€“ and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative. RSC Advances, 2015, 5, 39889-39898.	3.6	6
41	Structural characterization of LASSBio-1289: a new vasoactive N-methyl-N-acylhydrazone derivative. CrystEngComm, 2015, 17, 165-173.	2.6	10
42	Design, synthesis and inÂvitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 2015, 100, 24-33.	5.5	18
43	Novel Agonist of Adenosine Receptor Induces Relaxation of Corpus Cavernosum in Guinea Pigs: An InÂVitro and InÂVivo Study. Urology, 2015, 85, 1214.e17-1214.e21.	1.0	4
44	Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 62, 1-6.	4.8	4
45	Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes. Chinese Chemical Letters, 2015, 26, 721-726.	9.0	12
46	In vivo effect of LASSBio-785, a lipid-lowering and anti-inflammatory agent, on cardiac Ca2+-ATPases from hypercholesterolemic rats. International Journal of Cardiology, 2015, 201, 282-284.	1.7	2
47	3-Aminothiophene-2-Acylhydrazones: Non-Toxic, Analgesic and Anti-Inflammatory Lead-Candidates. Molecules, 2014, 19, 8456-8471.	3.8	10
48	Novel Potent Imidazo[1,2-a]pyridine-N-Glycinyl-Hydrazone Inhibitors of TNF-Î± Production: In Vitro and In Vivo Studies. PLoS ONE, 2014, 9, e91660.	2.5	16
49	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2014, 71, 1-14.	5.5	109
50	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. International Journal of Cardiology, 2014, 173, 154-162.	1.7	36
51	Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues. PLoS ONE, 2014, 9, e85380.	2.5	50
52	LASSBio-1135: A Dual TRPV1 Antagonist and Anti-TNF-Alpha Compound Orally Effective in Models of Inflammatory and Neuropathic Pain. PLoS ONE, 2014, 9, e99510.	2.5	13
53	Biotransformation of LASSBio-579 and pharmacological evaluation of p -hydroxylated metabolite a N -phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry, 2013, 62, 214-221.	5.5	14
54	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. European Journal of Medicinal Chemistry, 2013, 59, 64-74.	5.5	57

#	Article	IF	Citations
55	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	5.5	57
56	Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Journal of Medicinal Chemistry, 2013, 66, 122-134.	5.5	25
57	Beneficial effects of a novel agonist of the adenosine <scp>A_{2A}</scp> receptor on monocrotalineâ€induced pulmonary hypertension in rats. British Journal of Pharmacology, 2013, 169, 953-962.	5.4	37
58	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research, 2013, 237, 86-95.	2.2	26
59	Antihyperalgesic effects of a novel muscarinic agonist (<scp>LASSB</scp>ioâ€873) in spinal nerve ligation in rats. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 404-411.	1.9	8
60	Structure Re-determination of LASSBio-294 â€“ a cardioactive compound of the N-acylhydrazone class â€“ using X-ray powder diffraction data. Powder Diffraction, 2013, 28, S491-S509.	0.2	12
61	Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of N-acylhydrazone Derivatives. Molecules, 2013, 18, 11683-11704.	3.8	82
62	Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists. Current Topics in Medicinal Chemistry, 2012, 12, 2037-2048.	2.1	14
63	Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues. Molecules, 2012, 17, 14126-14145.	3.8	20
64	Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 264-271.	5.5	14
65	Potential Inhibitory Effect of LASSBio-596, a New Thalidomide Hybrid, on Inflammatory Corneal Angiogenesis in Rabbits. Ophthalmic Research, 2012, 48, 177-185.	1.9	12
66	Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 101-109.	5.2	6
67	Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7525-7545.	6.4	105
68	Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response. Molecules, 2012, 17, 14651-14672.	3.8	9
69	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	2.5	21
70	Synthesis and characterization of the atropisomeric relationships of a substituted Nâ€phenylâ€bipyrazole derivative with antiâ€inflammatory properties. Chirality, 2012, 24, 463-470.	2.6	2
71	Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. Journal of Molecular Modeling, 2012, 18, 2065-2078.	1.8	23
72	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	3.0	62

#	Article	IF	Citations
73	Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, 2011, 63, 1029-1039.	3.3	14
74	LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR. Toxicon, 2011, 58, 195-201.	1.6	20
75	Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 427-446.	1.2	13
76	Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H2LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H2LASSBio-1064) and Their Zinc(II) Complexes. Molecules, 2011, 16, 6902-6915.	3.8	48
77	The Methylation Effect in Medicinal Chemistry. Chemical Reviews, 2011, 111, 5215-5246.	47.7	671
78	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties. European Journal of Medicinal Chemistry, 2011, 46, 3000-3012.	5.5	32
79	CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. European Journal of Medicinal Chemistry, 2011, 46, 349-355.	5.5	7
80	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of IIºB kinase-Î². European Journal of Medicinal Chemistry, 2011, 46, 1245-1253.	5.5	22
81	Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LCâ€"MS/MS: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1024-1030.	2.8	7
82	Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064). Polyhedron, 2011, 30, 1891-1898.	2.2	39
83	MAOS and Medicinal Chemistry: Some Important Examples from the Last Years. Molecules, 2011, 16, 9274-9297.	3.8	18
84	Anti-inflammatory Profile of N-Phenylpyrazole Arylhydrazone Derivatives in Rats. Journal of Pharmacy and Pharmacology, 2010, 51, 703-707.	2.4	8
85	Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. Journal of Pharmacy and Pharmacology, 2010, 60, 699-707.	2.4	33
86	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 1925-1935.	3.0	57
87	Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2010, 18, 5007-5015.	3.0	53
88	Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. European Journal of Pharmacology, 2010, 638, 5-12.	3.5	25
89	Characterization of the conformational ensemble from bioactive N-acylhydrazone derivatives. Journal of Molecular Graphics and Modelling, 2010, 28, 446-454.	2.4	12
90	Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2888-2891.	2.2	7

#	Article	IF	Citations
91	Microwave-assisted synthesis and structureâ€"activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 74-77.	2.2	39
92	Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3734-3736.	2.2	14
93	Pharmacological Characterization of (3-Thienylidene)-3,4-Methylenedioxybenzoylhydrazide: A Novel Muscarinic Agonist With Antihypertensive Profile. American Journal of Hypertension, 2010, 23, 135-141.	2.0	19
94	Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR?. Toxicon, 2010, 56, 604-612.	1.6	25
95	Biodiversidade: fonte potencial para a descoberta de fÃ¡rmacos. Quimica Nova, 2009, 32, 679-688.	0.3	51
96	Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. Pharmacology Biochemistry and Behavior, 2009, 94, 70-74.	2.9	19
97	Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. European Journal of Medicinal Chemistry, 2009, 44, 3612-3620.	5.5	17
98	Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. European Journal of Medicinal Chemistry, 2009, 44, 4004-4009.	5.5	71
99	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. European Journal of Medicinal Chemistry, 2009, 44, 1959-1971.	5.5	10
100	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic and Medicinal Chemistry, 2009, 17, 74-84.	3.0	187
101	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 641-652.	3.0	94
102	Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: Orally effective anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 1125-1131.	3.0	35
103	Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole. Bioorganic and Medicinal Chemistry, 2009, 17, 6517-6525.	3.0	24
104	Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4963-4966.	2.2	48
105	From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’. Mini-Reviews in Medicinal Chemistry, 2009, 9, 782-793.	2.4	498
106	Synthesis and anti-platelet activity of novel arylsulfonateâ€"acylhydrazone derivatives, designed as antithrombotic candidates. European Journal of Medicinal Chemistry, 2008, 43, 348-356.	5.5	60
107	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (âˆ')-spectaline. European Journal of Pharmacology, 2008, 580, 339-349.	3.5	34
108	Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacology Biochemistry and Behavior, 2008, 89, 23-30.	2.9	14

#	Article	IF	Citations
109	Improved Solventâ€Free Dakin Oxidation Protocol. Synthetic Communications, 2008, 38, 784-788.	2.1	27
110	1-Methyl-7-(4-nitrophenyl)-3-phenylpyrazolo[3,4-b]pyrrolo[3,4-d]pyridine-6,8(3H,7H)-dione. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2356-o2356.	0.2	0
111	Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Current Medicinal Chemistry, 2007, 14, 1829-1852.	2.4	930
112	Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1108-1119.	2.4	266
113	The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies. Letters in Drug Design and Discovery, 2007, 4, 422-425.	0.7	3
114	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 2421-2433.	3.0	59
115	Aspectos quÃmicos, biolÃ³gicos e etnofarmacolÃ³gicos do gÃªnero Cassia. Quimica Nova, 2006, 29, 1279-1286.	0.3	36
116	Os produtos naturais e a quÃmica medicinal moderna. Quimica Nova, 2006, 29, 326-337.	0.3	93
117	Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFÎ± modulators. Bioorganic and Medicinal Chemistry, 2006, 14, 6874-6885.	3.0	16
118	Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: New lead-agents with analgesic and antipyretic properties. Bioorganic and Medicinal Chemistry, 2006, 14, 7924-7935.	3.0	80
119	Design, synthesis, and pharmacological evaluation of new neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives with in vivo hypnotic and analgesic profile. Bioorganic and Medicinal Chemistry, 2006, 14, 632-640.	3.0	41
120	Medicinal Chemistry of N-Acylhydrazones: New Lead-Compounds of Analgesic, Antiinflammatory and Antithrombotic Drugs. Current Medicinal Chemistry, 2006, 13, 167-198.	2.4	95
121	Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorganic and Medicinal Chemistry, 2005, 13, 3431-3437.	3.0	87
122	New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorganic and Medicinal Chemistry, 2005, 13, 4184-4190.	3.0	48
123	New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: Quantitative structureâ€"activity relationship studies. Bioorganic and Medicinal Chemistry, 2005, 13, 6336-6346.	3.0	36
124	Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1169-1172.	2.2	70
125	Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. European Journal of Pharmacology, 2005, 511, 219-227.	3.5	2
126	Electrospray ionization mass and tandem mass spectra of a series ofN-pyrazolylmethyl andN-triazolylmethylN-phenylpiperazines: new dopaminergic ligands with potential antipsychotic properties. Journal of Mass Spectrometry, 2005, 40, 815-820.	1.6	13

#	Article	IF	Citations
127	The molecular basis for coxib inhibition of p38Î± MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3506-3509.	2.2	13
128	New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2005, 5, 915-926.	2.4	39
129	Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design. Current Medicinal Chemistry, 2005, 12, 23-49.	2.4	563
130	LASSBio-468: a new achiral thalidomide analogue which modulates TNF-Î± and NO production and inhibits endotoxic shock and arthritis in an animal model. International Immunopharmacology, 2005, 5, 485-494.	3.8	19
131	New optimized piperamide analogues with potent in vivo hypotensive properties. European Journal of Pharmaceutical Sciences, 2004, 23, 363-369.	4.0	26
132	Further Bioactive Piperidine Alkaloids from the Flowers and Green Fruits ofCassiaspectabilis. Journal of Natural Products, 2004, 67, 908-910.	3.0	104
133	A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 3159-3166.	3.0	50
134	New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2004, 12, 3149-3158.	3.0	125
135	Synthesis and Pharmacological Evaluation of Novel Antinociceptive N-Substituted-phenylimidazolyl-4-acylhydrazone Derivatives.. ChemInform, 2003, 34, no.	0.0	0
136	Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2003, 11, 2051-2059.	3.0	168
137	Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 4807-4813.	3.0	67
138	Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres:Â A New Class of Potent and Selective Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1144-1152.	6.4	101
139	Antinociceptive Profile of (-)-Spectaline: A Piperidine Alkaloid fromCassia leptophylla. Planta Medica, 2003, 69, 795-799.	1.3	23
140	A quÃ¾mica medicinal de N-acilidrazonas: novos compostos-protÃ³tipos de fÃ¡rmacos analgÃ©sicos, antiinflamatÃ³rios e anti-trombÃ³ticos. Quimica Nova, 2002, 25, 129-148.	0.3	42
141	EstratÃ©gia de simplificaÃ§Ã£o molecular no planejamento racional de fÃ¡rmacos: a descoberta de novo agente cardioativo. Quimica Nova, 2002, 25, 1172-1180.	0.3	33
142	Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Il Farmaco, 2002, 57, 999-1007.	0.9	22
143	Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives designed as mefloquine analogues. Il Farmaco, 2002, 57, 825-832.	0.9	23
144	Molecular modeling of novel 1H-pyrazolo[3,4-b]pyridine derivatives designed as isosters of the antimalarial mefloquine. Computational and Theoretical Chemistry, 2002, 579, 31-39.	1.5	28

#	Article	IF	Citations
145	Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 9-12.	2.2	16
146	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	2.2	24
147	Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3067-3073.	3.0	174
148	New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. European Journal of Medicinal Chemistry, 2002, 37, 163-170.	5.5	37
149	Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. European Journal of Medicinal Chemistry, 2002, 37, 219-229.	5.5	27
150	SYNTHESIS OF NATURAL AMIDE ALKALOID PIPERDARDINE AND A NEW BIOACTIVE ANALOGUEâ€. Synthetic Communications, 2001, 31, 117-123.	2.1	10
151	Design and Synthesis of Novel Potent Antinociceptive Agents: Methyl-imidazolyl N-Acylhydrazone Derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 2243-2248.	3.0	47
152	Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole##This paper represents contribution # 36 of the LASSBio, UFRJ (Br.) (LASSBio,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td (htt Chemistry, 2000, 35, 187-203.	5.5	195
153	Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists. European Journal of Pharmaceutical Sciences, 2000, 11, 285-290.	4.0	37
154	O-Alkylation of Bioactive Phthalimide Derivatives Under Microwave Irradiation in Dry Media. Synthetic Communications, 2000, 30, 3291-3306.	2.1	11
155	New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole. Journal of the Brazilian Chemical Society, 1999, 10, 421-428.	0.6	9
156	Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 73, 281-292.	1.2	16
157	Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco, 1999, 54, 747-757.	0.9	31
158	Synthesis of Piperamides and New Analogues from Natural Safrole. Synthetic Communications, 1999, 29, 263-273.	2.1	10
159	A utilizaÃ§Ã£o do safrol, principal componente quÃmico do Ã³leo de sassafrÃ¡z, na sÃntese de substÃ¢ncias bioativas na cascata do Ã¡cido araquidÃ´nico: antiinflamatÃ³rios, analgÃ©sicos e anti-trombÃ³ticos. Quimica Nova, 1999, 22, 744-759.	0.3	37
160	Toward a platelet-activating factor pseudoreceptor: Semiempirical modeling of cation-Ï€ and hydrogen bond interactions in agonist binding. Computational and Theoretical Chemistry, 1998, 429, 217-227.	1.5	4
161	Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 183-188.	2.2	23
162	Synthesis and evaluation of analgesic, antiinflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 189-199.	5.5	188

#	Article	IF	Citations
163	Synthesis and antinociceptive properties of new structurally planned imidazo[1,2-a]pyridine 3-acylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 225-235.	5.5	61
164	Synthesis of New Benzylic Ethers of Oximes Derived from 1-Phenyl-pyrazole Compounds. Synthetic Communications, 1998, 28, 1299-1321.	2.1	6
165	Synthesis of new 1,2-Benzothiazin-3-one Derivatives Designed as Dual Cyclooxygenase-2 and 5-Lipooxygenase Inhibitors. Journal of the Brazilian Chemical Society, 1998, 9, 119-130.	0.6	7
166	Modelagem Molecular: Uma Ferramenta para o Planejamento Racional de FÃ¡rmacos em QuÃmica Medicinal. Quimica Nova, 1997, 20, 300-310.	0.3	18
167	The synthesis of new isochromanylacetylarylhydrazones designed as probable non-addictive analgesic agents. Journal of the Brazilian Chemical Society, 1997, 8, 471-478.	0.6	8
168	Design and Synthesis of a New 4-Oxa-8.OMEGA.-11-deoxy-5,6-dihydroprostacyclin Analogue.. Chemical and Pharmaceutical Bulletin, 1996, 44, 2157-2161.	1.3	11
169	Synthesis of condensed tricyclic pyrazolo[3,4-b]thieno[2,3-d]pyridine and related isostere derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 309-313.	2.6	8
170	Synthesis and analgesic properties of new 4-arylhydrazone 1-H pyrazole [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1996, 71, 213-219.	1.2	39
171	Synthesis and Anti-Platelet Evaluation of New Tricyclic PAF Antagonists, Designed as Structurally Related to Hetrazepine Class - Web 2086. Journal of the Brazilian Chemical Society, 1996, 7, 247-256.	0.6	7
172	Synthesis and analgesic properties of 5-acyl-arylhydrazone 1-H pyrazolo [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1994, 69, 163-169.	1.2	40
173	The Synthesis and Antiinflammatory Activity of 1-Alkyl-Isochroman-1-yl Acetic Acids Derivatives. Journal of the Brazilian Chemical Society, 1993, 4, 40-44.	0.6	9
174	Synthesis of pyrazole derivatives as potential bioisosteres of thromboxaneâ€synthetase inhibitors. Journal of Heterocyclic Chemistry, 1992, 29, 407-411.	2.6	9
175	The synthesis of a new benzothiazine derivative, related to oxicams, synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1992, 29, 1667-1669.	2.6	16
176	The Synthesis and Anti-inflammatory Properties of a New Sulindac Analogue Synthesized from Natural Safrole. Journal of Pharmaceutical Sciences, 1992, 81, 1219-1222.	3.3	20